HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dexcel Pharma Ltd.


Latest From Dexcel Pharma Ltd.

USP And Dexcel Pick Up Teva OTC Brands

Teva has struck a deal with USP in Poland that will see the Israeli company divest multiple consumer health brands. Meanwhile, Dexcel Pharma has acquired eight OTC brands from Teva in the UK.

Deals Strategy

UK’s Dexcel Pharma Snaps Up Eight OTC Brands From Teva

Dexcel Pharma has acquired eight OTC brands from Teva, including Bisodol Indigestion Relief Tablets, erectile dysfunction treatment Liberize and Yeast Vite supplements. Teva told HBW Insight it remains committed to the consumer health market despite a number of recent brand divestments.

United Kingdom Health

Finance Watch: $2.2bn In New Funding Sources In February, So Far

Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.

Financing Innovation

Eisai Exits Dermatology Through Roivant Deal

Eisai has followed in the footsteps of Japanese peer Astellas by divesting assets in the dermatology area, this time through a deal with Roivant for a clinical stage atopic dermatitis therapy that it sees as no longer fitting into its strategic priorities.

BioPharmaceutical Japan
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs